Synergistic Inhibition of Tumor Cell Proliferation by Cold Plasma and Gemcitabine

In the field of plasma medicine, cold atmospheric pressure plasma (CAP) is applied to biological matter for a therapeutic benefit. The latter is mediated by CAP-generated reactive species which treatment time-dependently either stimulate cells or induce their apoptosis. Accordingly, antitumor effects of plasma have been observed previously, but only few studies have included proper controls to compare the plasma's cytotoxicity. We here present results that murine cancer cells are more susceptible to CAP treatment compared to non-malignant fibroblasts in vitro. Additional challenge with the chemotherapeutic Gemcitabine significantly enhanced tumor cell but not fibroblast metabolic inhibition, suggesting potential combinatory effects in anticancer therapy.

[1]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[2]  P. Bruggeman,et al.  Nitric oxide density distributions in the effluent of an RF argon APPJ: effect of gas flow rate and substrate , 2014 .

[3]  N. Barekzi,et al.  Efficacy of Low Temperature Plasma against SCaBER Cancer Cells , 2014 .

[4]  Hiromasa Tanaka,et al.  Selective cytotoxicity of indirect nonequilibrium atmospheric pressure plasma against ovarian clear-cell carcinoma , 2014, SpringerPlus.

[5]  K. Weltmann,et al.  Tracking plasma generated H2O2 from gas into liquid phase and revealing its dominant impact on human skin cells , 2014 .

[6]  M. Hori,et al.  Perspective of strategic plasma therapy in patients with epithelial ovarian cancer: A short review of plasma in cancer treatment , 2014 .

[7]  A. Kramer,et al.  Hydrogen peroxide: A central player in physical plasma-induced oxidative stress in human blood cells , 2014, Free radical research.

[8]  Jürgen Schlegel,et al.  Plasma in Cancer Treatment , 2013 .

[9]  N. Barekzi,et al.  Effects of Low Temperature Plasmas on Cancer Cells , 2013 .

[10]  A. Kramer,et al.  Risk assessment of the application of tissue-tolerable plasma on human skin , 2013 .

[11]  A. Kramer,et al.  Tissue Tolerable Plasma (TTP) induces apoptosis in pancreatic cancer cells in vitro and in vivo , 2012, BMC Cancer.

[12]  T. von Woedtke,et al.  Plasma Processes and Plasma Sources in Medicine , 2012 .

[13]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[14]  T. von Woedtke,et al.  Experimental Recovery of CO2-Laser Skin Lesions by Plasma Stimulation , 2012 .

[15]  M. Lerch,et al.  A Syngeneic Orthotopic Murine Model of Pancreatic Adenocarcinoma in the C57/BL6 Mouse Using the Panc02 and 6606PDA Cell Lines , 2011, European Surgical Research.

[16]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[17]  Ronny Brandenburg,et al.  Atmospheric Pressure Plasma Jet for Medical Therapy: Plasma Parameters and Risk Estimation , 2009 .

[18]  S. Giordano,et al.  From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. , 2008, Current medicinal chemistry.

[19]  T. Minamoto,et al.  Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. , 2006, World journal of gastroenterology.

[20]  L. Attardi,et al.  The role of apoptosis in cancer development and treatment response , 2005, Nature Reviews Cancer.

[21]  E. Díaz-Rubio.  New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. , 2004, The oncologist.

[22]  J. Mackey,et al.  Nucleoside analogues and nucleobases in cancer treatment. , 2002, The Lancet. Oncology.

[23]  G. Peters,et al.  2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. , 1993, Biochemical pharmacology.

[24]  Dl Hoyert,et al.  National Vital Statistics Reports NCHS.pdf , 2012 .

[25]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[26]  T. Jacks,et al.  Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. , 2006, Cancer research.

[27]  J. Vermorken,et al.  Combined modality therapy of gemcitabine and radiation. , 2005, The oncologist.